Published :
Tables : 53
Figures : 48
Category : Healthcare
No. of Pages : 230
Report Code : HC-1201
Stem Cell Market is estimated to register a CAGR 8.8% during the forecast period 2022 to 2028. Advanced research in the development of biomaterial polymeric systems has resulted in a significant rise in recent years. These systems are instrumental in aiding the survival of stem cells which has boosted the market growth. Furthermore, advancements in the treatment of damaged tissues and diseased organs coupled with an increasing demand for regenerative medicines has propelled the market growth significantly. The adoption of stem cell has opened new opportunities for applications such as wound healing therapy which has assisted in the further augmentation of the market. The increased supply of biomaterial development used in stem cell transplantation and induced pluripotent stem cells (iPSCs) has revolutionised the stem cell sector. Such innovations allow researchers to create pluripotent stem cells from adult somatic cells which aid in preserving genetic information in these cells thus boosting the market growth. Based on the type of product, the market is categorised as adult stem cells, human embryonic stem cells, induced pluripotent stem cells and very small embryonic-like stem cells. The adult stem cell segment accounts for the largest market share and is predicted to continue this dominance during the forecast period. This is due to the low contamination risks linked to the minimal requirement of production labour, compatibility with the human body and sub-culturing. Pharmaceutical companies have profitable opportunities in the stem cell sector by initiating advancements in the identification of leading candidates thus allowing companies to develop novel drugs. Furthermore, extensive research has advanced the analysis of single-cell thus helping study the effects of drugs on cell differentiation. Additionally, the growing dependence of developing entities in cellular systems is projected to help the segment strengthen its market position in the upcoming years. Technology-wise, the market is bifurcated into cell acquisition, bone marrow harvest, apheresis, umbilical blood cord, cell production, therapeutic cloning, in-vitro fertilization, cell culture, isolation, expansion & sub-culture and cryopreservation. The cell production technology held the largest market share due to the current technological advancements aiming at satisfying the growing needs from different clinical applications. A soaring number of organ replacement approaches coupled with the rising demand for therapeutics has bolstered the market significantly. For instance, approximately 2200 transplant surgeries that were conducted in 2016 across the world were pancreas transplants. Depending on the type of therapy, the market is fragmented into autologous stem cell therapy and allogeneic stem cell therapy. Autologous stem cell therapy dominated the market concerning revenue generation in 2018. This is mainly attributed to the consumption of autologous products on a large scale owing to associative high compatibility. Additionally, meta-analytical studies on the effectiveness of autologous therapy for the treatment of lower limb disorders will propel the market further. Many companies are engaged in developing these autologous products for patients with sport-related injuries despite it being scrutinized by multiple government bodies. Regional Insights: The Asia Pacific region is projected to attain a remarkable CAGR over the forecast period. Developed economies like Australia, Singapore and Japan are extensively investing in the research and development projects which shall drive the market growth. Asia Pacific countries are likely to lead the rapidly evolving stem cell industry. Commercialization opportunities coupled with favourable regulatory policies bolster the market expansion. Japan, in particular, has initiated regulatory amendments related to regenerative medicine which has attracted international manufacturers to invest massively in the Japanese market. Key market players include Stemcell Technologies Inc., Celegene Corp., Osiris Therapeutics Inc., Biotime Inc., Advanced Cell Technology Inc. , Human Longevity Inc., Cynata, Promethera Biosciences, Mesoblast., Celgene Corporation, ReNeuron Group plc, Cytori Therapeutics, Inc., Cryo-Cell International Inc. Market Segmentation: By Product • Adult Stem Cells o Hematopoietic o Mesenchymal o Neural o Epithelial/Skin o Others • Human Embryonic Stem Cells • Induced Pluripotent Stem Cells (iPSCs) • Very Small Embryonic-like Stem Cells By Application • Regenerative Medicine o Neurology o Orthopaedics o Oncology o Haematology o Cardiovascular and Myocardial Infraction o Injuries o Diabetes o Liver Disorder o Incontinence o Others • Drug Discovery & Development By Technology • Cell Acquisition o Bone Marrow Harvest o Umbilical Blood Cord o Apheresis • Cell Production o Therapeutic Cloning o In vitro Fertilization o Cell Culture o Isolation • Cryopreservation • Expansion and Sub-culture By Therapy • Autologous • Allogenic By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Stem Cell Market Sample Video: Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects for stem cell market SWOT analysis Key trends in stem cell regeneration techniques Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the stem cell market by technology, by product, by application, by therapy and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencie Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Advanced research in the development of biomaterial polymeric systems has resulted in a significant rise in recent years. These systems are instrumental in aiding the survival of stem cells which has boosted the market growth. Furthermore, advancements in the treatment of damaged tissues and diseased organs coupled with an increasing demand for regenerative medicines has propelled the market growth significantly.
The adoption of stem cell has opened new opportunities for applications such as wound healing therapy which has assisted in the further augmentation of the market. The increased supply of biomaterial development used in stem cell transplantation and induced pluripotent stem cells (iPSCs) has revolutionised the stem cell sector. Such innovations allow researchers to create pluripotent stem cells from adult somatic cells which aid in preserving genetic information in these cells thus boosting the market growth.
Based on the type of product, the market is categorised as adult stem cells, human embryonic stem cells, induced pluripotent stem cells and very small embryonic-like stem cells. The adult stem cell segment accounts for the largest market share and is predicted to continue this dominance during the forecast period. This is due to the low contamination risks linked to the minimal requirement of production labour, compatibility with the human body and sub-culturing.
Pharmaceutical companies have profitable opportunities in the stem cell sector by initiating advancements in the identification of leading candidates thus allowing companies to develop novel drugs. Furthermore, extensive research has advanced the analysis of single-cell thus helping study the effects of drugs on cell differentiation. Additionally, the growing dependence of developing entities in cellular systems is projected to help the segment strengthen its market position in the upcoming years.
Technology-wise, the market is bifurcated into cell acquisition, bone marrow harvest, apheresis, umbilical blood cord, cell production, therapeutic cloning, in-vitro fertilization, cell culture, isolation, expansion & sub-culture and cryopreservation. The cell production technology held the largest market share due to the current technological advancements aiming at satisfying the growing needs from different clinical applications. A soaring number of organ replacement approaches coupled with the rising demand for therapeutics has bolstered the market significantly. For instance, approximately 2200 transplant surgeries that were conducted in 2016 across the world were pancreas transplants.
Depending on the type of therapy, the market is fragmented into autologous stem cell therapy and allogeneic stem cell therapy.
Autologous stem cell therapy dominated the market concerning revenue generation in 2018. This is mainly attributed to the consumption of autologous products on a large scale owing to associative high compatibility. Additionally, meta-analytical studies on the effectiveness of autologous therapy for the treatment of lower limb disorders will propel the market further. Many companies are engaged in developing these autologous products for patients with sport-related injuries despite it being scrutinized by multiple government bodies.
Regional Insights:
The Asia Pacific region is projected to attain a remarkable CAGR over the forecast period. Developed economies like Australia, Singapore and Japan are extensively investing in the research and development projects which shall drive the market growth. Asia Pacific countries are likely to lead the rapidly evolving stem cell industry. Commercialization opportunities coupled with favourable regulatory policies bolster the market expansion. Japan, in particular, has initiated regulatory amendments related to regenerative medicine which has attracted international manufacturers to invest massively in the Japanese market.
Key market players include Stemcell Technologies Inc., Celegene Corp., Osiris Therapeutics Inc., Biotime Inc., Advanced Cell Technology Inc. , Human Longevity Inc., Cynata, Promethera Biosciences, Mesoblast., Celgene Corporation, ReNeuron Group plc, Cytori Therapeutics, Inc., Cryo-Cell International Inc.
Market Segmentation:
By Product
• Adult Stem Cells o Hematopoietic o Mesenchymal o Neural o Epithelial/Skin o Others • Human Embryonic Stem Cells • Induced Pluripotent Stem Cells (iPSCs) • Very Small Embryonic-like Stem Cells
By Application
• Regenerative Medicine o Neurology o Orthopaedics o Oncology o Haematology o Cardiovascular and Myocardial Infraction o Injuries o Diabetes o Liver Disorder o Incontinence o Others • Drug Discovery & Development
By Technology
• Cell Acquisition o Bone Marrow Harvest o Umbilical Blood Cord o Apheresis • Cell Production o Therapeutic Cloning o In vitro Fertilization o Cell Culture o Isolation • Cryopreservation • Expansion and Sub-culture
By Therapy
• Autologous • Allogenic
By Region
• North America • Europe • Asia Pacific • Latin America • Middle East & Africa
Stem Cell Market Sample Video:
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Stem Cell Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Stem Cell Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Stem Cell Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Stem Cell Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Adult Stem Cells 7.1.1. Hematopoietic 7.1.2. Mesenchymal 7.1.3. Neural 7.1.4. Epithelial/Skin 7.1.5. Others 7.2. Human Embryonic Stem Cells 7.3. Induced Pluripotent Stem Cells (iPSCs) 7.4. Very Small Embryonic-like Stem Cells 8. Stem Cell Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Regenerative Medicine 8.1.1. Neurology 8.1.2. Orthopaedics 8.1.3. Oncology 8.1.4. Haematology 8.1.5. Cardiovascular and Myocardial Infraction 8.1.6. Injuries 8.1.7. Diabetes 8.1.8. Liver Disorder 8.1.9. Incontinence 8.1.10.Others 8.2. Drug Discovery & Development 9. Stem Cell Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Cell Acquisition 9.1.1. Bone Marrow Harvest 9.1.2. Umbilical Blood Cord 9.1.3. Apheresis 9.2. Cell Production 9.2.1. Therapeutic Cloning 9.2.2. In vitro Fertilization 9.2.3. Cell Culture 9.2.4. Isolation 9.3. Cryopreservation 9.4. Expansion and Sub-culture 10. Stem Cell Market, By Therapy Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Autologous 10.2. Allogenic 11. North America Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. STEMCELL Technologies Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Celegene Corp. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Osiris Therapeutics Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. BIOTIME Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Advanced Cell Technology Inc. 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Cytori Therapeutics 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Human Longevity Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Cynata 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Promethera Biosciences 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Mesoblast 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Celgene Corporation 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.ReNeuron Group plc 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Cryo-Cell International Inc. 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Clien
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Stem Cell Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Stem Cell Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Stem Cell Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Stem Cell Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Adult Stem Cells 7.1.1. Hematopoietic 7.1.2. Mesenchymal 7.1.3. Neural 7.1.4. Epithelial/Skin 7.1.5. Others 7.2. Human Embryonic Stem Cells 7.3. Induced Pluripotent Stem Cells (iPSCs) 7.4. Very Small Embryonic-like Stem Cells
8. Stem Cell Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Regenerative Medicine 8.1.1. Neurology 8.1.2. Orthopaedics 8.1.3. Oncology 8.1.4. Haematology 8.1.5. Cardiovascular and Myocardial Infraction 8.1.6. Injuries 8.1.7. Diabetes 8.1.8. Liver Disorder 8.1.9. Incontinence 8.1.10.Others 8.2. Drug Discovery & Development
9. Stem Cell Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Cell Acquisition 9.1.1. Bone Marrow Harvest 9.1.2. Umbilical Blood Cord 9.1.3. Apheresis 9.2. Cell Production 9.2.1. Therapeutic Cloning 9.2.2. In vitro Fertilization 9.2.3. Cell Culture 9.2.4. Isolation 9.3. Cryopreservation 9.4. Expansion and Sub-culture
10. Stem Cell Market, By Therapy Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Autologous 10.2. Allogenic
11. North America Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Stem Cell Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. STEMCELL Technologies Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Celegene Corp. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Osiris Therapeutics Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. BIOTIME Inc. 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Advanced Cell Technology Inc. 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Cytori Therapeutics 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Human Longevity Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Cynata 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Promethera Biosciences 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Mesoblast 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Celgene Corporation 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.ReNeuron Group plc 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Cryo-Cell International Inc. 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Clien
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics